



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

31 May 2021 (#15)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Important Notices

**[NOT-RM-21-029](#) Notice Announcing Data Generation Projects for the NIH Bridge to Artificial Intelligence (Bridge2AI) Program (OT2) Other Transaction Opportunity Announcement.** This Notice announces the publication of a new Research Opportunity Announcement (ROA), Data Generation Projects for the [NIH Bridge to Artificial Intelligence \(Bridge2AI\) Program](#), and the key dates for submitting Letters of Intent (LOI) and full proposals. The ROA was released on the [NIH Common Fund website](#). Non-domestic (non-U.S.) Entities (Foreign Applicants) are eligible to apply. The overall goal of the Bridge2AI Program is to generate flagship datasets and best practices for the collection and preparation of AI/ML-ready data to address biomedical and behavioral research grand challenges. The Bridge2AI program will require multiple scientific domains to come together with data science, data management and analytic experts to unlock the potential of AI/ML for the scientific community. Data Generation Project Letter of Intent (LOI) Due Date (Required): 20 July 2021. Full Proposal Deadline, due by 5 p.m. submitter's local time: 20 August 2021. The planned budget for this effort is approximately \$96 million over a 4-year period. NIH anticipates making 5-8 data generation awards.

**[NOT-CA-21-081](#) Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Target Discovery and Development (CTD2) (U01 Clinical Trial Not Allowed).** CTD2 will promote efforts to radically improve our understanding of the underlying etiology of cancer initiation, progression, and metastasis and to exploit this knowledge in clinically relevant context which includes intra-tumor heterogeneity, tumor microenvironment and other factors that result in "innate" or acquired treatment resistance. Each U01 application budget will be limited to \$750,000 direct cost per year for a total of five years. Non-domestic (non-U.S.) Entity (Foreign Organization) will be eligible to apply. This Notice of Intent to Publish (NOITP) is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

**[NOT-HD-21-032](#) Notice of Special Interest (NOSI): Reduction of Sudden Unexpected Infant Death and Sudden Infant Death Syndrome.** Eunice Kennedy Shriver National Institute of Child Health and Human Development ([NICHD](#)) Invite basic science, clinical researchers, behavioral scientists and implementation science experts either as individual or as multi-disciplinary teams, to submit research projects that will identify risk-reduction strategies that address infant mortality domestically, as well as efforts to understand the root causes of sudden infant death syndrome and sudden unexpected infant death. This notice applies to standard due dates starting with cycle III, 2021 (after 16 June 2021) and subsequent receipt dates through 8 May 2023. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

- [PA-20-183](#) - Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-185](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-200](#) - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Funding Opportunity Announcements (FOA)

### 1. Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-21-230](#)

**Type:** D43

**Application Due Date:** 13 August 2021; 13 July 2022; 13 July 2023 Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This funding opportunity announcement (FOA) encourages applications for the Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) D43 program for institutional research training programs in low-and middle-income countries (LMICs, as defined by the World Bank classification system). Applications may be for collaborations between institutions in the U.S and an eligible LMIC or may involve just LMIC institutions if there is a previous track record of externally funded research and/or research training programs by the lead LMIC institution. The proposed institutional research training program is expected to sustainably strengthen the NCD research capacity of the LMIC institutions, and to train in-country experts to develop and conduct research on NCDs across the lifespan, with the long-range goal of developing and implementing evidence-based interventions relevant to their countries. Interdisciplinary research training that cuts across NCDs is encouraged. However, for more topical applications, the main focus of research training covered in the application must be relevant to the mission and/or interests of at least one of the participating NIH ICs, other than FIC, as stated by each in this FOA. Other NCD topics and types of training may be included as secondary and complementary focus areas. This Funding Opportunity Announcement (FOA) allows appointment of Trainees (D43) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

**Budget:** Application budgets are limited to \$230,000 per year for new awards and \$250,000 per year for renewal awards (total direct costs). The maximum project period is up to 5 years.

### 2. Mechanistic studies on the impact of social inequality on the substance use trajectory (R21 - Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-DA-22-005](#)

**Type:** R21

**Application Due Date:** October 14, 2021. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This funding opportunity announcement (FOA) invites mechanistic studies on the impact of social inequality on the brain and on the substance use trajectory. Applications investigating relevant mechanisms at the behavioral, cognitive, neurocircuitry, cellular, genetics, and epigenetics levels are encouraged. Exploratory and high-risk research projects are appropriate for this FOA. Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data should consider applying to the companion R01 announcement [RFA-DA-22-007](#).

**Budget:** National Institute on Drug Abuse (NIDA) intends to commit \$2,000,000 in FY 2022 to fund 4-6 awards in response to this FOA and the companion FOAs. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is 2 years.

### 3. Assessing the Effects of Cannabinoids on HIV-Associated Persistent Inflammation (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-DA-22-012](#)

**Type:** R01

**Application Due Date:** August 05, 2021. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage basic science and preclinical research to determine the biological mechanisms underlying 1) the effects of cannabinoids and the endocannabinoid system on HIV-associated persistent inflammation, and 2) its consequent effects on nervous system function. Projects submitted in response to this FOA must include expertise and resources in both areas of HIV/AIDS and addiction science.

**Budget:** NIDA intends to fund an estimate of 3-5 awards, corresponding to a total of \$2 million, for fiscal year 2022. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

**4. Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R01 Basic Experimental Studies with Humans Required)**

**Letter of Intent: 30 days prior to the application due date**

**Hyperlink: [RFA-DA-22-024](#)**

**Type: R01**

**Application Due Date:** October 14, 2021. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This funding opportunity announcement (FOA) invites mechanistic studies on the impact of social inequality on the brain and on the substance use trajectory. Applications investigating relevant mechanisms at the behavioral, cognitive, neurocircuitry, cellular, genetics, and epigenetics levels are encouraged.

Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data are appropriate for this FOA. Applicants with exploratory and high-risk research projects should consider applying to the companion R01 announcement [RFA-DA-22-030](#).

**Budget:** NIDA intends to commit \$2 million in FY 2022 to fund 4-6 awards in response to this FOA and the companion FOAs. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

**5. Adapting Immunotherapy and Gene Editing Based Strategies for Targeting HIV Reservoirs in the CNS: Potential Benefits and Risks (R01 Clinical Trial Optional)**

**Letter of Intent: 30 days prior to the application due date**

**Hyperlink: [RFA-MH-21-225](#)**

**Type: R01**

**Application Due Date:** August 27, 2021. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites research grant applications that propose studies for adapting immunotherapy and gene therapy-based strategies to target viral reservoirs in the central nervous system (CNS) and examine the potential risks of applying such technologies to the brain. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborations are encouraged but not required. High risk/high payoff projects that lack preliminary data may be most appropriate for the companion R21 FOA, [RFA-MH-21-226](#), while applicants with preliminary data may wish to apply using the R01 mechanism.

**Budget:** NIMH intends to commit a total of \$2,000,000 in FY 2022 to fund 3-5 awards in response to this FOA and the companion FOA. NINDS intends to commit a total of \$1,500,000 in FY22 to fund 2-3 awards in response to this FOA and the companion FOA. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105